Advertisement

Topics

Adamas nets $134.6mm through FOPO

19:41 EST 26 Jan 2018 | Elsevier Business Intelligence

Adamas Pharmaceuticals Inc. (developing memantine-based CNS drugs) netted $134.6mm through a public offering of $3.45mm share...

Original Article: Adamas nets $134.6mm through FOPO

NEXT ARTICLE

More From BioPortfolio on "Adamas nets $134.6mm through FOPO"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Neurology - Central Nervous System (CNS)
Alzheimer's Disease Anesthesia Anxiety Disorders Autism Bipolar Disorders Dementia Epilepsy Multiple Sclerosis (MS) Neurology Pain Parkinson's Disease Sleep Disorders Neurology is the branch of me...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Epilepsy
Epilepsy is defined as a disorder of brain function characterized by recurrent seizures that have a sudden onset.  (Oxford Medical Dictionary).  A seizure is caused by a sudden burst of excess electrical activity in the brain, causing a tempora...